<DOC>
	<DOCNO>NCT01446991</DOCNO>
	<brief_summary>This study investigate efficacy Degarelix , Luteinizing Hormone Releasing Hormone ( LHRH ) antagonist , reduce prostate volume prior permanent seed prostate brachytherapy . There 2 eligible population men , select brachytherapy treatment choice prostate cancer . Either enlarge prostate require size reduction render brachytherapy technically feasible , require androgen ablation conjunction brachytherapy optimal tumor control . The hypothesis Degarelix provide &gt; 30 % volume reduction 3 month &gt; 30 % men .</brief_summary>
	<brief_title>Feasibility Toxicity Degarelix Prostate Downsizing Prior Permanent Seed Prostate Brachytherapy</brief_title>
	<detailed_description>All men baseline transrectal ultrasound brachytherapy planning demonstrate enlarged prostate without pubic arch obstruction . After sign informed consent document load dose 240 mg Degarelix monthly maintenance dose injection 80 mg time sufficient prostate reduction occur ( 2-3 month ) complete 6 month require androgen ablation disease status .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologic diagnosis prostate cancer Favorable risk disease ( cT1 T2a , Gleason score ( GS ) 6 , Prostate Specific Antigen ( PSA ) &lt; 10 ng/mL ) Lowtier intermediate risk disease ( cT2c , GS=6 , PSA 1015 ng/mL , OR GS=7 PSA &lt; 10 ng/mL ) Intermediate risk disease AND androgen deprivation therapy recommend treat physician oncologic reason ( ≥ 50 % positive biopsy core , cT2c , PSA 1520 ng/mL , GS=7 ) Patient require baseline plan transrectal ultrasound purpose prostate brachytherapy , show prostate volume &gt; 40 mL pubic arch interference ( require require androgen ablation oncologic reason ) castrate serum testosterone level previous concurrent pelvic radiotherapy unable give write informed consent contraindication permanent seed prostate brachytherapy androgen deprivation therapy prior treatment prostate cancer prior transurethral resection prostate previous therapy 5α reductase inhibitor , antiandrogen agent , LHRH agonist previous therapy degarelix</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prostate neoplasm</keyword>
	<keyword>brachytherapy</keyword>
	<keyword>androgen ablation</keyword>
	<keyword>benign prostatic hypertrophy</keyword>
	<keyword>prostate size reduction</keyword>
	<keyword>localized prostate cancer prostate volume &gt; 40 cc</keyword>
</DOC>